Ritu Agarwal, MD
- ASSISTANT PROFESSOR | Medicine, Liver Diseases
Specialties:Liver Medicine, Gastroenterology
American Board of Internal Medicine
Residency, Internal Medicine, Mount Sinai School of Medicine
Fellowship, Gastroenterology, Mount Sinai Hospital
- A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Naïve Subjects with Chronic HCV Infection
The purpose of this study is to evaluate the efficacy, safety, and tolerability of SOF/VEL/GS-9857 in comparison to SOF/VEL in patients infected with HCV. Information about any side effects that may occur will also be collected.
This is a randomized, open-label...
- A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study toInvestigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects with Chronic HCV Infection
The purpose of this study is to evaluate the efficacy, safety, and tolerability of SOF/VEL/GS-9857 FDC in patients infected with HCV. This is a randomized, double-blind, placebo-controlled study. Patients will be screened to see if they have genotype 1 HCV. If so, they will be...
- Simeprevir (SMV)+Sofosbuvir (SOF) with or without Ribavirin (RBV) for Interferon-intolerant or ineligible (IFN-II) Patients with Chronic Hepatitis C (CHC)
The purpose of this study is to investigate the safety and effectiveness of a combination of simeprevir 150 mg daily plus Sofosbuvir 400 mg daily with or without Ribavirin for 12 weeks in patients who are intolerant and/or ineligible to receive Interferon therapy. This is an “...